Renalytix Reports Full Year Fiscal 2023 Results

6 months ago

LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled…

Matinas BioPharma to Present at Two Investment Conferences in October 2023

6 months ago

BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining…

Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece

6 months ago

-- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology ---- PoNS system and mouthpiece will be…

StateHouse Holdings Appoints Zed Schlott as Vice President of Retail

6 months ago

Cannabis industry veteran brings over a decade of experience in retail operations, leadership and business analysisSAN DIEGO and TORONTO, Sept.…

Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

6 months ago

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a…

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

6 months ago

Pre-registration for the LinkedIn Live event will begin on Thursday, September 28th Industry experts to discuss the need for non-abstinence-based…

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

6 months ago

SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and…

Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting

6 months ago

The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the efficacy of AT-001 (caficrestat) on cardiac functional capacity in…

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

6 months ago

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersThe…

XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023

6 months ago

CALGARY, Alberta, Sept. 28, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX…